Drug Profile
Research programme: MAP kinase activated kinase 2 inhibitors - Moerae Matrix
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Moerae Matrix
- Class Peptides
- Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Fibrosis in USA
- 20 Jun 2012 Preclinical trials in Fibrosis in USA (unspecified route)